Earnings Call Summary | Cardiff Oncology(CRDF.US) Q2 2024 Earnings Conference
Earnings Call Summary | Cardiff Oncology(CRDF.US) Q2 2024 Earnings Conference
Updated cash runway guidance indicates resources lasting until the end of Q3 2025.The following is a summary of the Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript:
以下是cardiff oncology公司（CRDF）2024年第二季度業績會會議記錄摘要：
Financial Performance:
金融業績：
As of June 30, 2024, cash and short-term investments totaled $60.3 million.
Cash used in operating activities for Q2 2024 was $9.2 million.
Updated cash runway guidance indicates resources lasting until the end of Q3 2025.
截至2024年6月30日，現金和短期投資總額爲6030萬美元。
2024年第二季度運營活動所使用現金爲920萬美元。
更新的現金儲備指南顯示，資源可維持至2025年第三季度結束。
Business Progress:
業務進展：
Cardiff Oncology is progressing with the CRDF-004 trial in RAS-mutated metastatic colorectal cancer.
Plans to enroll 90 patients in the CRDF-004 trial across 33 sites.
Additionally, a new investigator-initiated trial combining onvansertib with NALIRIFOX for first-line metastatic PDAC is planned, following the approval of NALIRIFOX.
Cardiff Oncology正在推進RAS突變轉移性結直腸癌CRDF-004試驗。
計劃在33個研究中心招募90名CRDF-004試驗患者。
此外，在NALIRIFOX獲批准後，計劃組合onvansertib和NALIRIFOX在轉移性PDAC一線治療中的應用。
Opportunities:
機會：
Onvansertib shows potential in various cancer subtypes beyond colorectal, including pancreatic and ovarian cancers.
Preclinical studies suggest onvansertib's efficacy in overcoming resistance to PARP inhibitors in ovarian cancer.
Onvansertib在多種癌症亞型中顯示出潛力，包括胰腺和卵巢癌。
臨床前研究表明Onvansertib在克服卵巢癌中PARP抑制劑的耐藥性方面有效。
Risks:
風險：
No explicit risks detected.
沒有發現任何明確風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。